Cover Image
市場調查報告書

P2X嘌呤受體3 (P2RX3) :開發中產品分析

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364861
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
P2X嘌呤受體3 (P2RX3) :開發中產品分析 P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 52 Pages
簡介

本報告提供以P2X嘌呤受體3 (P2RX3) 為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

P2X嘌呤受體3 (P2RX3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Afferent Pharmaceuticals, Inc.
  • Asana BioSciences, LLC
  • Integral Molecular, Inc.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.
  • 鹽野義製藥

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0919TDB

Summary:

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein that in humans is encoded by the P2RX3 gene. It belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel and may transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 3 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Respiratory, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Neuropathic Pain, Chronic Cough, Chronic Pain, Hypertension, Visceral Pain, Abdominal Pain, Alzheimer's Disease, Endometriosis, Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome), Memory Impairment, Migraine, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain, Pain, Resistant Hypertension and Respiratory Tract Infections.

The latest report P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
  • The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • P2X Purinoceptor 3 (P2RX3) - Overview
    • P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
    • Asana BioSciences LLC
    • Bayer AG
    • BELLUS Health Inc
    • Integral Molecular Inc
    • Merck & Co Inc
    • Neurim Pharmaceuticals Ltd
    • Pfizer Inc
  • P2X Purinoceptor 3 (P2RX3) - Drug Profiles
    • AF-130 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize P2X3 for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gefapixant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-300 Backups - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • P2X Purinoceptor 3 (P2RX3) - Dormant Products
  • P2X Purinoceptor 3 (P2RX3) - Discontinued Products
  • P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
    • Featured News & Press Releases
      • May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
      • Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
      • Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
      • Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
      • Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease
      • Sep 05, 2016: Hypertension: releasing the pressure at its source
      • May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference
      • May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
      • Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
      • Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference
      • Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial
      • Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients
      • Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
      • Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome
      • Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Asana BioSciences LLC, H2 2017
  • Pipeline by Bayer AG, H2 2017
  • Pipeline by BELLUS Health Inc, H2 2017
  • Pipeline by Integral Molecular Inc, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top